Manual de Quimioterapia Del Cáncer / / edited by Roland T. Skeel, Samir N. Khleif ; traducción Beatriz Magri Ruiz, M. Jesús del Sol Jaquotot |
Edizione | [Eight edition.] |
Pubbl/distr/stampa | Barcelona : , : Wolters Kluwer Health, , [2012] |
Descrizione fisica | 1 online resource (891 pages) |
Disciplina | 616.99406 |
Collana | Elibro Cátedra |
Soggetto topico |
Cancer - Treatment
Chemotherapy |
ISBN |
84-18563-05-2
84-15684-38-X |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | spa |
Nota di contenuto |
Cover -- Preliminares -- SECCIÓN I: CONSIDERACIONES Y PRINCIPIOS BÁSICOS DE LA QUIMIOTERAPIA Y EL TRATAMIENTO DIRIGIDO CONTRA DIANAS MOLECULARES RACIONALES -- Capítulo 1. Basebiológica y farmacológica de la quimioterapia del cáncer -- Capítulo 2. Bases biológicas del tratamiento dirigido contra dianas moleculares -- Capítulo 3. Evaluación sistemática del enfermo de cáncer y consecuencias del tratamiento -- Capítulo 4. Selección del tratamiento para el pacientecon cáncer -- SECCIÓN II: QUIMIOTERAPIA Y TRATAMIENTO DIRIGIDO CONTRA DIANAS MOLECULARES DEL CÁNCER HUMANO -- Capítulo 5. Carcinomas de cabeza y cuello -- Capítulo 6. Carcinoma broncopulmonar -- Capítulo 7. Carcinomas del tubodigestivo -- Capítulo 8. Carcinomas pancreático, hepático, de la vesícula biliar y de los conductos biliares -- Capítulo 9. Carcinoma de mama -- Capítulo 10. Cáncer ginecológico -- Capítulo 11. Cáncer urológico y genital masculino -- Capítulo 12. Cáncer renal -- Capítulo 13. Carcinomas tiroideos y suprarrenales -- Capítulo 14. Melanomas y otras neoplasias cutáneas malignas -- Capítulo 15. Tumores cerebrales primarios y metastásicos -- Capítulo 16. Sarcomas de partes blandas -- Capítulo 17. Sarcomas óseos -- Capítulo 18. Leucemias agudas -- Capítulo 19. Leucemias crónicas -- Capítulo 20. Neoplasias mieloproliferativas y síndromes mielodisplásicos -- Capítulo 21. Linfoma de Hodgkin -- Capítulo 22. Linfoma no hodgkiniano -- Capítulo 23. Mieloma múltiple, otros trastornos de células plasmáticas y amiloidosis primaria -- Capítulo 24. Carcinoma metastásico de origen desconocido -- Capítulo 25. Neoplasias malignas asociadas al virus dela inmunodeficiencia humana -- SECCIÓN III: TRATAMIENTO COMPLEMENTARIO DE LOS PACIENTES ONCOLÓGICOS -- Capítulo 26. Efectos secundarios de la quimioterapia y del tratamiento dirigido contra dianas moleculares.
Capítulo 27. Etiología, tratamiento y prevención de las infecciones en el paciente oncológico -- Capítulo 28. Tratamiento con hemoderivados, hemorragia y coagulación -- Capítulo 29. Urgencias oncológicas y problemas relacionados con los cuidados intensivos: compresión medular, edema cerebral, síndrome de la vena cava superior, anafilaxia, insuficiencia respiratoria, síndrome de lisis tumoral, hipercalcemia y metástasis ósea -- Capítulo 30. Derrames pleurales, peritoneales y pericárdicos, e infiltrados meníngeos neoplásicos -- Capítulo 31. Dolor asociado con el cáncer -- Capítulo 32. Problemas emocionales y psiquiátricos en el paciente oncológico -- SECCIÓN IV: ANTINEOPLÁSICOS Y FÁRMACOS DIRIGIDOS CONTRA DIANAS MOLECULARES Y SU USO -- Capítulo 33. Clasificación, uso y toxicidad de la quimioterapia y el tratamiento dirigido contra dianas moleculares de utilidad clínica -- Apéndice A. Nomograma para determinar el área de superficie corporal en personas adultas a partir de la masa y la altura* -- Apéndice B. Nomograma para determinar el área de superficie corporal en la infancia a partir de la masa y la altura* -- ÍNDICE ALFABÉTICO DE MATERIAS. |
Record Nr. | UNINA-9910793487403321 |
Barcelona : , : Wolters Kluwer Health, , [2012] | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Manual de Quimioterapia Del Cáncer / / edited by Roland T. Skeel, Samir N. Khleif ; traducción Beatriz Magri Ruiz, M. Jesús del Sol Jaquotot |
Edizione | [Eight edition.] |
Pubbl/distr/stampa | Barcelona : , : Wolters Kluwer Health, , [2012] |
Descrizione fisica | 1 online resource (891 pages) |
Disciplina | 616.99406 |
Collana | Elibro Cátedra |
Soggetto topico |
Cancer - Treatment
Chemotherapy |
ISBN |
84-18563-05-2
84-15684-38-X |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | spa |
Nota di contenuto |
Cover -- Preliminares -- SECCIÓN I: CONSIDERACIONES Y PRINCIPIOS BÁSICOS DE LA QUIMIOTERAPIA Y EL TRATAMIENTO DIRIGIDO CONTRA DIANAS MOLECULARES RACIONALES -- Capítulo 1. Basebiológica y farmacológica de la quimioterapia del cáncer -- Capítulo 2. Bases biológicas del tratamiento dirigido contra dianas moleculares -- Capítulo 3. Evaluación sistemática del enfermo de cáncer y consecuencias del tratamiento -- Capítulo 4. Selección del tratamiento para el pacientecon cáncer -- SECCIÓN II: QUIMIOTERAPIA Y TRATAMIENTO DIRIGIDO CONTRA DIANAS MOLECULARES DEL CÁNCER HUMANO -- Capítulo 5. Carcinomas de cabeza y cuello -- Capítulo 6. Carcinoma broncopulmonar -- Capítulo 7. Carcinomas del tubodigestivo -- Capítulo 8. Carcinomas pancreático, hepático, de la vesícula biliar y de los conductos biliares -- Capítulo 9. Carcinoma de mama -- Capítulo 10. Cáncer ginecológico -- Capítulo 11. Cáncer urológico y genital masculino -- Capítulo 12. Cáncer renal -- Capítulo 13. Carcinomas tiroideos y suprarrenales -- Capítulo 14. Melanomas y otras neoplasias cutáneas malignas -- Capítulo 15. Tumores cerebrales primarios y metastásicos -- Capítulo 16. Sarcomas de partes blandas -- Capítulo 17. Sarcomas óseos -- Capítulo 18. Leucemias agudas -- Capítulo 19. Leucemias crónicas -- Capítulo 20. Neoplasias mieloproliferativas y síndromes mielodisplásicos -- Capítulo 21. Linfoma de Hodgkin -- Capítulo 22. Linfoma no hodgkiniano -- Capítulo 23. Mieloma múltiple, otros trastornos de células plasmáticas y amiloidosis primaria -- Capítulo 24. Carcinoma metastásico de origen desconocido -- Capítulo 25. Neoplasias malignas asociadas al virus dela inmunodeficiencia humana -- SECCIÓN III: TRATAMIENTO COMPLEMENTARIO DE LOS PACIENTES ONCOLÓGICOS -- Capítulo 26. Efectos secundarios de la quimioterapia y del tratamiento dirigido contra dianas moleculares.
Capítulo 27. Etiología, tratamiento y prevención de las infecciones en el paciente oncológico -- Capítulo 28. Tratamiento con hemoderivados, hemorragia y coagulación -- Capítulo 29. Urgencias oncológicas y problemas relacionados con los cuidados intensivos: compresión medular, edema cerebral, síndrome de la vena cava superior, anafilaxia, insuficiencia respiratoria, síndrome de lisis tumoral, hipercalcemia y metástasis ósea -- Capítulo 30. Derrames pleurales, peritoneales y pericárdicos, e infiltrados meníngeos neoplásicos -- Capítulo 31. Dolor asociado con el cáncer -- Capítulo 32. Problemas emocionales y psiquiátricos en el paciente oncológico -- SECCIÓN IV: ANTINEOPLÁSICOS Y FÁRMACOS DIRIGIDOS CONTRA DIANAS MOLECULARES Y SU USO -- Capítulo 33. Clasificación, uso y toxicidad de la quimioterapia y el tratamiento dirigido contra dianas moleculares de utilidad clínica -- Apéndice A. Nomograma para determinar el área de superficie corporal en personas adultas a partir de la masa y la altura* -- Apéndice B. Nomograma para determinar el área de superficie corporal en la infancia a partir de la masa y la altura* -- ÍNDICE ALFABÉTICO DE MATERIAS. |
Record Nr. | UNINA-9910810435603321 |
Barcelona : , : Wolters Kluwer Health, , [2012] | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
The medical letter on drugs and therapeutics |
Pubbl/distr/stampa | New Rochelle, NY, : Medical Letter, Inc |
Disciplina | 615 |
Soggetto topico |
Drug interactions
Drugs Pharmacology Chemotherapy Pharmaceutical Preparations Therapeutics |
Soggetto genere / forma |
Periodical
Periodicals. |
ISSN | 1523-2859 |
Formato | Materiale a stampa |
Livello bibliografico | Periodico |
Lingua di pubblicazione | eng |
Altri titoli varianti | Medical letter |
Record Nr. | UNINA-9910684592503321 |
New Rochelle, NY, : Medical Letter, Inc | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
The medical letter on drugs and therapeutics |
Pubbl/distr/stampa | New Rochelle, NY, : Medical Letter, Inc |
Disciplina | 615 |
Soggetto topico |
Drug interactions
Drugs Pharmacology Chemotherapy Pharmaceutical Preparations Therapeutics |
Soggetto genere / forma |
Periodical
Periodicals. |
ISSN | 1523-2859 |
Formato | Materiale a stampa |
Livello bibliografico | Periodico |
Lingua di pubblicazione | eng |
Altri titoli varianti | Medical letter |
Record Nr. | UNISA-996518461503316 |
New Rochelle, NY, : Medical Letter, Inc | ||
Materiale a stampa | ||
Lo trovi qui: Univ. di Salerno | ||
|
Medical pharmacology and therapeutics / / Derek G. Waller, Anthony P. Sampson |
Autore | Waller Derek |
Edizione | [Fifth edition.] |
Pubbl/distr/stampa | Edinburgh : , : Elsevier, , 2018 |
Descrizione fisica | 1 online resource (vi, 729 pages) : color illustrations |
Disciplina | 615.1 |
Soggetto topico |
Pharmacology
Chemotherapy Pharmaceutical Preparations Pharmacological Phenomena Drug Therapy Pharmacology, Clinical - methods |
ISBN | 0-7020-7190-0 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Section 1: General principles. Principles of pharmacology and mechanisms of drug action -- Pharmacokinetics -- Drug discovery, safety and efficacy -- Neurotransmission and the peripheral autonomic nervous system -- Section 2: The cardiovascular system. Ischaemic heart disease -- Systemic and pulmonary hypertension -- Heart failure -- Cardiac arrhythmias -- Cerebrovascular disease and dementia -- Peripheral vascular disease -- Haemostasis -- Section 3: The respiratory system. Asthma and chronic obstructive pulmonary disease -- Respiratory disorders: Cough, respiratory stimulants, cystic fibrosis, idiopathic pulmonary fibrosis and neonatal respiratory distress syndrome -- Section 4: The renal system. Diuretics -- Disorders of micturition -- Erectile dysfunction -- Section 5: The nervous system. General anaesthetics -- Local anaesthetics -- Opioid analgesics and the management of pain -- Anxiety, obsessive-compulsive disorder and insomnia -- Schizophrenia and bipolar disorder -- Depression, attention deficit hyperactivity disorder and narcolepsy -- Epilepsy -- Extrapyramidal movement disorders and spasticity -- Other neurological disorders: Multiple sclerosis, motor neuron disease and Guillain-Barré syndrome -- Migraine and other headaches -- Section 6: The musculoskeletal system. The neuromuscular junction and neuromuscular blockade -- Myasthenia gravis -- Nonsteroidal antiinflammatory drugs -- Rheumatoid arthritis, other inflammatory arthritides and osteoarthritis -- Hyperuricaemia and gout -- Section 7: The gastrointestinal system. Nausea and vomiting -- Dyspepsia and peptic ulcer disease -- Inflammatory bowel disease -- Constipation, diarrhoea and irritable bowel syndrome -- Liver disease -- Obesity -- Section 8: The immune system. The immune response and immunosuppressant drugs -- Antihistamines and allergic disease -- Section 9: The endocrine system and metabolism. Diabetes mellitus -- The thyroid and control of metabolic rate -- Calcium metabolism and metabolic bone disease -- Pituitary and hypothalamic hormones -- Corticosteroids (glucocorticoids and mineralocorticoids -- Female reproduction -- Androgens, antiandrogens and anabolic steroids -- Anaemia and haematopoietic colony-stimulating factors -- Lipid disorders -- Section 10: The skin and eyes. Skin disorders -- The eye -- Section 11: Chemotherapy. Chemotherapy of infections -- Chemotherapy of malignancy -- Section 12: General features: drug toxicity and prescribing. Drug toxicity and overdose -- Substance abuse and dependence -- Prescribing, adherence and information about medicines -- Drug therapy in special situations. |
Record Nr. | UNINA-9910583335603321 |
Waller Derek | ||
Edinburgh : , : Elsevier, , 2018 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Medicinal Chemistry / / edited by Janka Vašková and Ladislav Vaško |
Pubbl/distr/stampa | London, United Kingdom : , : IntechOpen, , 2019 |
Descrizione fisica | 1 online resource (168 pages) |
Disciplina | 615.19 |
Soggetto topico |
Chemotherapy
Pharmaceutical chemistry |
ISBN |
1-83962-077-3
1-78985-174-2 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910317957403321 |
London, United Kingdom : , : IntechOpen, , 2019 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Medikamentöse Therapie des Genital- und Mammakarzinoms / / M. Kaufmann, F. Kubli, P. Drings, H. Burkert, G. Bastert |
Autore | Kaufmann M |
Edizione | [4., überarbeitete und erweiterte Auflage.] |
Pubbl/distr/stampa | Basel : , : S. Karger, , 1989 |
Descrizione fisica | 1 online resource (XIII + 106 pages) : : 7 figures, 11 tables |
Soggetto topico |
Oncology
Chemotherapy Gynecology |
ISBN | 3-318-04929-8 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | ger |
Record Nr. | UNINA-9910151828803321 |
Kaufmann M | ||
Basel : , : S. Karger, , 1989 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Messenger RNA therapeutics / / Stefan Jurga and Jan Barciszewski |
Autore | Jurga Stefan |
Pubbl/distr/stampa | Cham, Switzerland : , : Springer International Publishing, , [2022] |
Descrizione fisica | 1 online resource (451 pages) |
Disciplina | 615.58 |
Collana | RNA Technologies Ser. |
Soggetto topico |
Chemotherapy
Chemotherapy - Social aspects |
ISBN | 3-031-08415-2 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Intro -- Introduction: IVT Messenger RNA in the Syringe -- Contents -- Roadmap to the Development of mRNA Therapeutics: From Molecule Design and Delivery Strategies to Manufacturing, Quality Control, and Regulatory Considerations -- 1 Introduction -- 2 mRNA Design Strategies -- 2.1 Reducing mRNA Immunogenicity -- 2.2 Optimizing Protein Expression -- 2.3 Optimizing mRNA Stability -- 3 Delivery Strategies for mRNA Therapeutics -- 3.1 Lipid Nanoparticles for mRNA Delivery -- 3.2 Other Materials for mRNA Delivery -- 3.3 mRNA Drug Product Route of Administration -- 4 Manufacturing of mRNA Drug Products -- 4.1 mRNA Drug Substance Manufacturing -- 4.2 mRNA Drug Product Manufacturing -- 5 Quality Control of mRNA Therapeutics -- 5.1 Drug Substance (mRNA) CQAs and Quality Control Strategy -- 5.2 Drug Product (mRNA-LNPs) CQAs and Quality Control Strategy -- 6 Conclusion and Future Directions -- References -- Messenger RNA for Prophylaxis -- 1 Introduction -- 2 mRNA Vaccines: Categories and Biological Function -- 3 Advances in mRNA Constructs -- 3.1 5' Capping -- 3.2 Untranslated Regions (UTRs) -- 3.3 Poly(A)-Tail -- 3.4 Nucleotide Modification and Codon Optimization -- 3.5 Purity -- 3.6 Self-Amplifying Specific Features -- 4 mRNA Carrier Technologies -- 4.1 Tropism and Uptake Efficiency -- 4.2 The Art of Endosomal Escape -- 4.3 Formulation -- 4.4 Stability -- 5 Conclusions -- References -- Messenger RNA Therapeutics: Start of a New Era in Medicine -- 1 Introduction -- 2 Production of IVT mRNA -- 3 Immunogenicity of IVT mRNA -- 4 Strategies to Increase the Stability and Reduce the Immunogenicity of IVT mRNA -- 4.1 Capping (m7GpppN or m7Gp3N) -- 4.2 Tailing -- 4.3 Untranslated Regions (UTRs) -- 4.4 Coding Region -- 5 Purification of Synthetic mRNA -- 6 Synthetic mRNA Platforms and their Features -- 6.1 Unmodified mRNA -- 6.2 Modified mRNA.
6.3 Sequence-Optimized Unmodified mRNA -- 6.4 Replicon RNA -- 7 In Vivo Delivery Strategies of Exogenous mRNA -- 7.1 Delivery of Naked mRNA -- 7.2 Cationic Liposome-Mediated or Cationic Nanoemulsion (CNE)-based RNA Transfection -- 7.3 Peptide-based Delivery -- 7.4 Electroporation and Nucleoporation -- 7.5 Gene Gun-Mediated Delivery of mRNA -- 7.6 Use of Polymer Nanomaterials -- 7.7 Virus-like Replicon Particle (VRP)-based Delivery of mRNA -- 7.8 Other Lesser-Known Methods -- 8 Applications of mRNA Therapeutics -- 8.1 mRNA as a Therapeutic Agent for Replacement of Defective Protein within the Cell -- 8.2 mRNA as Vaccines Against Cancer -- 8.3 Dendritic Cell (DC) Vaccines -- 8.4 mRNA Vaccines in Prevention of Diseases -- 8.5 mRNA-Mediated Genome Editing -- 8.6 Generation of Induced Pluripotent Stem Cells (iPSCs) using mRNA -- 9 Safety of mRNA Therapeutics -- 9.1 The Safety Concern Over the Use of Non-Natural Nucleotides/Nucleosides in IVT mRNA -- 9.2 Safety Considerations Regarding the Encoded Protein -- 10 Conclusions -- References -- Hospital-Based RNA Therapeutics -- 1 Introduction -- 2 A Role for Hospital-Based Drug Development -- 3 Manufacturing of mRNA -- 4 Innovations in mRNA Therapeutics -- 4.1 Reducing Immunogenicity -- 4.2 Cell-Specific/Tissue-Specific Delivery and Translation -- 4.3 Increasing mRNA Stability and Expression -- 5 Applications of RNA Therapeutics -- 6 Conclusion and Future Perspective -- References -- Medical Use of mRNA-Based Directed Gene Delivery -- 1 Introduction -- 2 Gene Delivery with mRNA Versus DNA -- 2.1 The Comparison -- 2.2 Improving IVT mRNA for Clinical Use -- 3 Targeted LNPs -- 4 Extracellular Vesicles (EVs, Aka Exosomes) -- 4.1 mRNA Loading of EVs -- 4.2 Strategies to Target mRNA-Loaded EVs and Their Therapeutic Use -- 4.3 Improving EVs for Clinical Use -- 5 Conclusion -- References. SARS-COV-2 and Other mRNA Vaccines -- 1 Introduction: The Successes of MRNA-LNP Vaccines for SARS-COV-2 -- 2 Pfizer-BioNTech-BNT162b2 (Comirnaty)-mRNA-LNP SARS-COV-2 Vaccine -- 2.1 Clinical Phase 1 Study in Adults (19-55 years), Germany -- 2.2 Clinical Phase 1 Study in Adults (18-55 and 65-85 years), U.S. -- 2.3 Clinical Phase 2/3, (16 Years of Age or Older) Multi-Country -- 2.4 Post-licensure Effectiveness, Safety Surveillance and Boosting -- 3 Moderna-mRNA-1273 (Spikevax) mRNA-LNP SARS-COV-2 Vaccine -- 3.1 Clinical Phase 1 Trial in Adults and Older Adults, U.S. -- 3.2 Clinical Phase 2 Trial (18 Years of Age and Older), US -- 3.3 Clinical Phase 3 Efficacy Trial in Adults (18 Years of Age or Older), U.S. -- 3.4 Post-Licensure Effectiveness, Safety Surveillance and Boosting -- 4 CureVac CVnCoV -- 4.1 Clinical Phase 1 Trial (18-60 Years of Age), Germany and Belgium -- 4.2 Clinical Phase 2b/3 Efficacy Trial (18 Years of Age and Over), Multi-Country -- 5 Overall Interpretation of Safety and Efficacy Data for mRNA-LNP Vaccines Against SARS-COV-2 -- 6 Other mRNA SARS-COV-2 Candidate Vaccines -- 7 Clinical-Stage mRNA Candidate Vaccines Against Other Non-COVID-19 Infectious Diseases -- 8 Future mRNA Technology Advances -- References -- Pulmonary Delivery of Messenger RNA (mRNA) Therapeutics for Respiratory Diseases -- 1 Introduction -- 2 Pulmonary RNA Delivery Systems -- 2.1 Lipid-Based Delivery System -- 2.2 Polymer-Based Delivery System -- 2.3 Peptide-Based Delivery System -- 2.4 Modified Naked mRNA -- 3 mRNA Strategies and Respiratory Diseases -- 3.1 Cystic Fibrosis -- 3.2 Asthma -- 3.3 Respiratory Syncytial Virus Infection -- 3.4 Antiviral Effect Using Cas13 -- 3.5 Vaccines Against Respiratory Viral Infections -- 4 Summary and Future Prospects -- References. Synthetic mRNA Gene Therapies and Hepatotropic Non-viral Vectors for the Treatment of Chronic HBV Infections -- 1 Introduction -- 2 Gene and Epigenome Editing Technologies to Disable HBV -- 2.1 HBV Designer Nucleases and Base Editors -- 2.2 HBV Epigenome Modifiers -- 3 Developing mRNA as Therapeutics -- 3.1 Enhancing Translation and Stability of Synthetic mRNA -- 3.2 Liver-Specific Delivery of mRNA Using Non-viral Vectors -- 4 The Future of HBV mRNA Therapy -- References -- Preparation of Synthetic mRNAs-Overview and Considerations -- 1 Introduction -- 1.1 Synthetic mRNAs -- 1.2 Kinds of Synthetic mRNAs -- 1.3 Key Structural Attributes for a Functional Synthetic mRNA -- 1.4 Chemical Modifications of Synthetic mRNA -- 1.5 The mRNA Cap -- 2 Platforms for mRNA Synthesis -- 2.1 Restriction Enzymes for Template Linearization -- 2.2 RNA Polymerase -- 2.3 RNase Inhibitor -- 2.4 Inorganic Pyrophosphatase -- 2.5 DNase I -- 2.6 Capping Enzyme -- 2.7 Poly-A Polymerase -- 3 Purification of the Synthetic mRNA -- 4 Analyses of Synthetic mRNAs -- 4.1 Capping Efficiency -- 4.2 Poly-A Tail Length -- 5 Perspective and Future Directions -- References -- In Vitro-Transcribed mRNAs as a New Generation of Therapeutics in the Dawn of Twenty-First Century: Exploitation of Peptides as Carriers for Their Intracellular Delivery -- 1 In Vitro-Transcribed mRNA as a Powerful Gene Therapy Tool -- 2 Advances in the Delivery of IVT-mRNA -- 3 Peptide-Based Systems for IVT-mRNA Delivery -- 4 Cell-Penetrating Peptides or Protein Transduction Domains -- 5 Strategies to Generate a PTD/Nucleic Acid Complex -- 5.1 Non-covalent Conjugation Approach for IVT-mRNA Delivery via Peptides -- 5.2 Covalent Conjugation Approach for IVT-mRNA Delivery via Peptides -- 6 Future Perspectives -- References. Lipid Nanoparticle-Mediated Delivery of Therapeutic and Prophylactic mRNA: Immune Activation by Ionizable Cationic Lipids -- 1 Introduction -- 2 Cytosolic Delivery of mRNA -- 3 Lipid Nanoparticles (LNPs) as Delivery Systems for mRNA -- 4 Immune Activation by Lipids Used for mRNA Delivery -- 5 Conclusions -- References -- Adjuvants, the Elephant in the Room for RNA Vaccines -- 1 Introduction -- 2 mRNA as a Natural Adjuvant -- 2.1 Endosomal RNA Recognition -- 2.2 Cytoplasmic RNA Sensors -- 3 Type I IFNs: The Double-Edged Sword -- 3.1 Nucleoside Modifications -- 3.2 Techniques for dsRNA Removal -- 3.3 Role of Type I IFN Receptor -- 4 mRNA Delivery Systems -- 5 Conclusion -- References -- Advances in mRNA Delivery and Clinical Applications -- 1 Introduction -- 2 Lipid Nanoparticles -- 3 Polymers -- 4 Lipid-Polymer Hybrid Nanoparticles -- 5 Polypeptides -- 6 Other Carriers -- 7 Applications of Therapeutic mRNA -- 7.1 Vaccine -- 7.2 Protein-Replacement Therapy -- 7.3 Gene Editing -- 8 Discussion and Perspectives -- References -- Lipid Nanoparticles to Harness the Therapeutic Potential of mRNA for Cancer Treatment -- 1 Introduction -- 2 Structure, Synthesis, and Purification of in Vitro Transcribed (IVT) mRNA -- 2.1 Structural Organization of IVT-mRNA -- 2.2 Synthesis of IVT-mRNA -- 2.3 Purification of Synthetic mRNA -- 3 Lipid Nanoparticles for Therapeutic mRNA Delivery -- 4 mRNA-Based Cancer Immunotherapy: Antitumor Vaccines -- 4.1 mRNA-Loaded LNP-Mediated Monoclonal Antibody Delivery -- 4.2 mRNA-Loaded LNPs for CAR Immune Cell Engineering -- 5 Future Prospective and Conclusions -- References -- RNA/Polymer-Based Supramolecular Approaches for mRNA Delivery -- 1 Introduction -- 2 Polymeric Assemblies -- 2.1 Polyplexes -- 2.2 Polymeric Micelles -- 3 RNA Architectonics -- 4 Combination of RNA Architectonics and Polymeric Micelles -- 5 Conclusion. References. |
Record Nr. | UNINA-9910595061703321 |
Jurga Stefan | ||
Cham, Switzerland : , : Springer International Publishing, , [2022] | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|
Molecole contro i microbi / E.S. Duthie |
Autore | Duthie, Edward Stephens |
Pubbl/distr/stampa | Milano : Longanesi, 1949 |
Descrizione fisica | 258 p. : ill. ; 19 cm |
Disciplina | 615.1 |
Collana | Panorami scientifici ; 11 |
Soggetto topico |
Chemotherapy
Pharmaceutical chemistry |
Classificazione | LC RM663 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | ita |
Record Nr. | UNISALENTO-991003895609707536 |
Duthie, Edward Stephens | ||
Milano : Longanesi, 1949 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. del Salento | ||
|
Monoclonal Antibodies in Tumor Therapy : : Present Stage, Chances and Limitations / / H.H. Sedlacek, G. Schulz, A. Steinstraesser, L. Kuhlmann, A. Schwarz, L. Seidel, G. Seemann, H.-P. Kraemer, K. Bosslet |
Autore | Sedlacek H.H |
Pubbl/distr/stampa | Basel : , : S. Karger, , 1988 |
Descrizione fisica | 1 online resource (X + 178 pages) : : 18 figures, 57 tables |
Altri autori (Persone) | SedlacekH. H |
Soggetto topico |
Oncology
Biochemistry Immunology Chemotherapy Pharmacokinetics Radiology |
ISBN | 3-318-03415-0 |
Formato | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Record Nr. | UNINA-9910156322203321 |
Sedlacek H.H | ||
Basel : , : S. Karger, , 1988 | ||
Materiale a stampa | ||
Lo trovi qui: Univ. Federico II | ||
|